Our laboratory is interested in identifying prognostic and predictive biomarkers in myeloproliferative neoplasms (MPN) and other bone marrow failure states. The MPN are a diverse group of hematologic cancers that includes diseases including chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), mastocytosis, chronic neutrophilic leukemia, chronic eosinophilic leukemia and MPN unclassifiable.
Diseases like PV, ET and PMF can be complicated by thrombotic events, worsening cytopenia, risk for transformation to acute myeloid leukemia while diseases like mastocytosis and chronic eosinophilic leukemia can be complicated by organ infiltration. With the exception of CML, no effective therapies exist for most cases of Philadelphia chromosome negative MPN.
My laboratory intends to identify novel molecular markers using whole genome scanning technologies, such as single nucleotide polymorphism arrays and next generation genomic sequencing technologies, to help in the elucidation of disease pathogenesis which can subsequently be used to help predict which patients with specific MPNs are more likely to respond to certain biologic treatments.
Conversely, the identification of specific biomarkers may also be prognostic, allowing for improvement of risk stratification schemes. Techniques utilized include flow cytometry, RT-PCR, next generation genomic sequencing, single nucleotide polymorphism arrays and other molecular biology techniques.